BioPharmSignal logoBioPharmSignal

Biotech News

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRx (CVRX)CVRxEarnings

MINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and

Open original release

Related news

CVRXCVRx2026-04-27 20:30 EST

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

CVRXCVRx2026-04-13 12:00 EST

CVRx Reports Preliminary First Quarter 2026 Financial Results

ICCMIceCure Medical2026-05-06 12:30 EST

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

STIMNeuronetics2026-05-05 11:50 EST

Neuronetics Reports First Quarter 2026 Financial and Operating Results

STIMNeuronetics2026-04-21 12:30 EST

Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

AORTArtivion2026-05-07 20:05 EST

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

DNLIDenali Therapeutics2026-05-07 20:01 EST

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

NAMSNewAmsterdam Pharma2026-05-07 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

SGHTSight Sciences2026-05-06 20:05 EST

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

MNKDMannKind2026-05-06 20:01 EST

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

View all latest news

CVRx

CVRx is a medical device company focused on neuromodulation therapies for heart failure and hypertension-related conditions. Its products aim to address cardiovascular disease through implanted device technology.

Recent company news

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

CVRXCVRx2026-05-14 12:00 EST

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRXCVRx2026-05-04 20:30 EST

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Stock data

Close
4.88 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States